解説予定演題一覧 score (tps) ≥ 1%: open-label, phase 3 keynote-042 study. plenary session...

解説演題一覧

肺がん

婦人科がん

脳腫瘍

血液がん

解説：後藤功一

解説：藤原恵一

解説：永根基雄

解説 : 畠清彦

2018 年 6 月 7 日現在

【肺がん】表紙に戻る

Abstract No. Authour Title Session Type

LBA4 Gilberto Lopes, MD, MBAPembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study

Plenary Session

105 Luis G. Paz-Ares, MD, PhDPhase 3 study of carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab for metastatic squamous non-small cell lung cancer (NSCLC)

Clinical Science Symposium

9002 Mark A. Socinski, MDOverall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC

Oral Abstract Session

LBA9000 Robert M. Jotte, MD, PhDIMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC


9001 Hossein Borghaei, DO, MSNivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy in chemo-naive patients with advanced non-small cell lung cancer and <1% tumor PD-L1 expression: Results from CheckMate 227


9009 Dong-Wan Kim, MD, PhDSafety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK + advanced NSCLC (aNSCLC)


8500 Greg Andrew Durm, MDPhase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179


8507 David Paul Carbone, MD, PhDEfficacy and safety of rovalpituzumab tesirine (Rova-T™) in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study


8506 Hyun Cheol Chung, MD, PhDPhase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158


102 Alexander E. Drilon, MDLIBERETTO-001: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET -altered cancers


9004 Tony Mok, MD, FASCODacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis


9005 Atsushi Nakamura, PhD, MD

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)


9006 Naoki Furuya, MD, PhDPhase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR -mutations: NEJ026


9007 Noboru Yamamoto, MD, PhDErlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): Survival follow-up results of JO25567


【婦人科がん】表紙に戻る


5501 Robert L. Coleman, MD

A phase III randomized controlled trial of secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab in platinum-sensitive, recurrent ovarian cancer: A NRG Oncology/Gynecologic Oncology Group study


5506 Sandro PignataChemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17


5500 Takashi Onda, MD, PhDComparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602


5505 Martee Leigh Hensley, MDAdjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III NRG Oncology/Gynecologic Oncology Group study


5511 Ursula A. Matulonis, MDAntitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study


5594 Kosei HasegawaEfficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers

Poster Session

【脳腫瘍】表紙に戻る


2001 Michael Platten, MDTargeting IDH1R132H in WHO grade III/IV IDH1R132H-mutated gliomas by a peptide vaccine - a Phase I safety, tolerability and immunogenicity multicenter trial (NOA-16)


2002 Ingo K. Mellinghoff, MDPhase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma


2005 Anna Luisa Di StefanoActionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype


2006 David A. Reardon, MDPhase II study of pembrolizumab or pembrolizumab plus bevacizumab in recurrent glioblastoma (rGBM)


2009 Sarah B. Goldberg, MDDurability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab

Poster Session

2013 Michael Weller, MDDifferential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma

Poster Session

2014 Carlos Kamiya-Matsuoka, MD The natural course of hypermutator gliomas Poster Session

【血液がん】表紙に戻る


7500 Nathan Hale Fowler, MDRELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R²) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma (FL)


7507 Laurie Helen Sehn, MD, MPHRandomized phase 2 trial of polatuzumab vedotin with bendamustine and rituximab in relapsed/refractory FL and DLBCL


3003 Frederick Lundry Locke, MDDurability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma


7505 Jeremy S. Abramson, MDUpdated safety & long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL


8007 Noopur Rajebb2121 anti-BCMA CAR T cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study


7502 William G. Wierda, MD, PhDPhase 2 CAPTIVATE results of ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia (CLL)


7508 Peter Hillmen, M.B., Ch.B.High, durable minimal residual disease negativity with venetoclax + rituximab in relapsed/refractory CLL: Minimal residual disease kinetics from phase 3 MURANO study


8004 Luciano J. CostaPhase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma


解説予定演題一覧 score (tps) ≥ 1%: open-label, phase 3 keynote-042 study. plenary session...

Documents